Jacob Sands

Also affiliated with Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).”.

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9507

N/A

1.5DataRank · unranked

39 citations

Daniel B. Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari +13 more

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis

JCO Precision Oncology(2020)10.1200/po.20.00121

N/A

1.5DataRank · unranked

29 citations

Evan W. Clark, Marina S.D. Milan, Christine Champagne, Kesi Michael, Mark M. Awad +10 more

The design and evaluation of hybrid controlled trials that leverage external data and randomization

Nature Communications(2022)10.1038/s41467-022-33192-1

N/A

1.0DataRank · unranked

34 citations

Sean Khozin, Bill Louv, Jacob Sands, Patrick Y. Wen, Rifaquat Rahman +4 more

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9077

N/A

0DataRank · unranked

31 citations

Sumithra J. Mandrekar, Geoffrey R. Oxnard, David Kozono, Shauna L. Hillman, Suzanne E. Dahlberg +13 more

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.02.009

N/A

0DataRank · unranked

26 citations

Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker +13 more

Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts.

Cancer Treatment and Research Communications(2021)10.1016/j.ctarc.2021.100486

N/A

0DataRank · unranked

9 citations

Jiarui Zhang, Travis Sullivan, Xingyi Shi, Jacob Sands, Shawn M. Regis +10 more